Cipla is one of the companies in India that has been licensed to manufacture and market Remdesivir to cure COVID-19. This is likely to be a big opportunity for Cipla once the necessary DGCI approvals are through.

The other thing is that Cipla has a strong domestic market franchise in the pharma industry and that makes Cipla less vulnerable to the vagaries of the US FDA. This makes Cipla a safer bet among the Indian pharma stocks.

Traders can look to buy Cipla at the current market price but ideally they should buy the stock on dips. For long term investors there could more traction in the upside over the next couple of years.